Stage IV Pancreatic Cancer

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (02-5-2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco,... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (12-25-2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a study published in the New England Journal of Medicine. Pancreatic... Continue Reading

Abraxane Approved for Metastatic Pancreatic Cancer (09-20-2013)

The U.S. Food and Drug Administration (FDA) has approved Abraxane® (paclitaxel protein-bound particles for injectable suspension, albumin-bound) for the treatment of patients with metastatic pancreatic cancer. Pancreatic cancer is one of the deadliest... Continue Reading

Abraxane Improves Survival in Pancreatic Cancer (02-13-2013)

Abraxane® (nab-paclitaxel) prolonged life in patients with metastatic pancreatic cancer by an average of two months longer than chemotherapy and significantly increased the percentage of patients who survived for up to two years, according to the results... Continue Reading

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET) (06-2-2011)

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells... Continue Reading

Novel Chemotherapy Regimen Outperforms Gemzar for Pancreatic Cancer (05-18-2011)

For people with metastatic pancreatic cancer, the chemotherapy combination known as FOLFIRINOX results in better overall survival than standard treatment with Gemzar® (gemcitabine), but also increases side effects. These results were published in the... Continue Reading

Afinitor Approved for Pancreatic Neuroendocrine Tumors (05-10-2011)

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing... Continue Reading

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer (04-1-2011)

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal Science. Immune therapies stimulate the body’s... Continue Reading

Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes (02-23-2011)

Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not result in better outcomes than treatment with Gemzar alone. The results of this Phase III clinical trial... Continue Reading

Sutent and Afinitor Show Promise against Advanced Pancreatic Neuroendocrine Tumors (02-22-2011)

In two separate Phase III clinical trials, the targeted drugs Sutent® (sunitinib) and Afinitor® (everolimus) delayed the progression of advanced pancreatic neuroendocrine tumors. These results were published in the New England Journal of Medicine. Pancreatic... Continue Reading

« Previous PageNext Page »